Ipamorelin

What Ipamorelin is

Ipamorelin (developmental code NNC 26-0161) is a synthetic pentapeptide with the amino-acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, making it a member of the growth hormone-releasing peptide (GHRP) family ^[1]. It was originally developed by Novo Nordisk in Denmark and emerged from a major medicinal chemistry programme aimed at identifying potent GH secretagogues that lacked the central dipeptide Ala-Trp found in the parent compound GHRP-1 ^[1]. Its discovery was first reported in a landmark 1998 paper by Raun and colleagues in the European Journal of Endocrinology, which described it as the first selective growth hormone secretagogue—a compound capable of stimulating GH release with a specificity profile comparable to endogenous growth hormone-releasing hormone (GHRH) ^[1].

As a GHS-R1a agonist, ipamorelin belongs to a broader class of compounds—growth hormone secretagogues—that increase GH release by mimicking or potentiating ghrelin signalling ^[4]. What distinguished ipamorelin within this class at the time of its discovery was its failure to significantly elevate adrenocorticotropic hormone (ACTH) or cortisol—effects seen with related compounds such as GHRP-2 and GHRP-6—even at multiples of the GH-releasing concentration ^[1][2]. This hormonal selectivity made it a valued research tool and later a candidate for clinical development, though it has never received regulatory approval for human therapeutic use in any jurisdiction ^[7].

What it is being researched for

1. Growth hormone release and pituitary pharmacology

Ipamorelin's primary research application is as a probe for pituitary GH secretion. In vitro studies using primary rat pituitary cells showed it released GH with potency and efficacy comparable to GHRP-6, and pharmacological profiling with GHRP and GHRH antagonists confirmed it acts through a GHRP-like receptor pathway ^[1]. A pharmacokinetic-pharmacodynamic modelling study in healthy human volunteers by Gobburu and colleagues (1999) characterised ipamorelin's behaviour in people, reporting dose-proportional GH release with a terminal plasma half-life of approximately two hours and a single, discrete GH pulse peaking around 40 minutes after administration before returning to baseline within roughly three hours ^[5]. This pulsatile kinetic profile is considered physiologically relevant because it preserves the natural hypothalamic feedback loop that regulates GH secretion, in contrast to continuous exogenous GH delivery ^[4].

2. Hormonal selectivity and cortisol/ACTH sparing

A defining feature of ipamorelin in preclinical research is its lack of effect on the hypothalamic-pituitary-adrenal (HPA) axis. In conscious swine, administration of GHRP-2 and GHRP-6 produced measurable increases in plasma ACTH and cortisol, whereas ipamorelin did not raise ACTH or cortisol levels significantly above those seen after GHRH stimulation—and this was observed even at concentrations more than 200-fold above the GH-releasing ED₅₀ ^[1][2]. Similarly, ipamorelin did not affect FSH, LH, prolactin, or TSH in these models ^[1]. This selectivity profile has made ipamorelin a useful research comparator for isolating GH-axis effects from broader neuroendocrine responses, and it underpinned the original designation of ipamorelin as the first GHRP-receptor agonist with GH release selectivity comparable to GHRH ^[2].

3. Bone mineral content and skeletal biology

Ipamorelin has been studied in rodent models for its effects on bone. A 2000 study by Svensson and colleagues in the Journal of Endocrinology investigated whether ipamorelin and GHRP-6 could increase bone mineral content (BMC) in young adult female rats over a 12-week period ^[6]. All treatments, including ipamorelin, increased total body and tibial BMC as measured by DXA in vivo; in vitro pQCT measurements showed the gains in cortical BMC were attributable to increased cross-sectional bone area and bone dimensions rather than a change in volumetric bone mineral density ^[6]. Separately, a 1999 study by Johansen and colleagues demonstrated that ipamorelin induced statistically significant longitudinal bone growth in hypophysectomised rats, suggesting that the GH released by ipamorelin is biologically active at the tissue level ^[3]. These findings remain preclinical, and no published human trials have evaluated ipamorelin's effects on bone density.

4. Body composition and nitrogen metabolism

Animal research has examined ipamorelin's potential to counteract catabolism. A study by Aagaard and colleagues (2009) in Growth Hormone & IGF Research used a prednisolone-treated rat model of steroid-induced catabolism to investigate whether GH or ipamorelin could mitigate nitrogen wasting ^[8]. In prednisolone-treated animals, ipamorelin reduced a key marker of nitrogen wasting (CUNS) by approximately 20%, decreased expression of urea cycle enzymes, normalised nitrogen balance, and normalised or improved organ nitrogen content, though somewhat less efficiently than exogenous GH at the doses studied ^[8]. The authors concluded that the GH secretagogue exerts GH-related metabolic effects and may be relevant to studying steroid-induced catabolism ^[8]. These findings are limited to animal models, and no equivalent human body-composition trials have been published ^[9].

5. Gastrointestinal motility and postoperative ileus

Because ghrelin and ghrelin-receptor agonists are known to have prokinetic effects in the gut, ipamorelin was studied as a potential treatment for postoperative ileus (POI). A preclinical study by Venkova and colleagues (2009) in the Journal of Pharmacology and Experimental Therapeutics showed that ipamorelin accelerated gastrointestinal transit and increased faecal pellet output in a rodent model of POI ^[7]. This led to a Phase 2 randomised, double-blind, placebo-controlled clinical trial (NCT00672074) by Beck, Sweeney, and McCarter (2014), enrolling 117 patients undergoing open or laparoscopic bowel resection ^[10]. The primary efficacy endpoint—time to tolerance of a standardised solid meal—was not met: median time to first tolerated meal was 25.3 hours in the ipamorelin group versus 32.6 hours in the placebo group, a difference that was not statistically significant (p = 0.15) ^[10]. The FDA subsequently noted that this Phase 2 trial did not demonstrate significant differences in colonic function between ipamorelin and placebo, and its clinical development for POI was discontinued ^[7].

6. Regulatory status and safety considerations

Ipamorelin has never received regulatory approval for any human therapeutic indication from the FDA, Health Canada, or the EMA. In September 2023, the FDA added ipamorelin acetate to the Category 2 bulk drug substances list under Section 503B of the FD&C Act, meaning it is classified as presenting significant safety risks and is prohibited from use in compounded medications [6a]. The FDA's safety concerns cited the potential for immunogenicity due to aggregation or peptide-related impurities, the presence of unnatural amino acids that complicate characterisation, and a report of serious adverse events including death in an IV study aimed at improving gastric motility [6a]. The FDA also noted it lacked sufficient information about certain other routes of administration to determine whether the compound would be safe [6a]. The PCAC reviewed ipamorelin acetate in October 2024, and no new approval status has been granted.

How it is thought to work

Ipamorelin exerts its effects by binding to and activating the growth hormone secretagogue receptor subtype 1a (GHS-R1a), the same G-protein-coupled receptor that is activated by the endogenous hormone ghrelin ^[1][4]. GHS-R1a is expressed predominantly on somatotroph cells in the anterior pituitary, and its activation initiates an intracellular signalling cascade: the receptor couples to the Gq/11 G-protein family, activating phospholipase C, which generates inositol trisphosphate (IP3) and triggers mobilisation of intracellular calcium. This calcium rise drives fusion of GH-containing secretory vesicles with the plasma membrane, releasing stored GH as a discrete, pulsatile burst ^[4]. Pharmacological profiling using both GHRP and GHRH antagonists confirmed that ipamorelin stimulates GH release specifically through this GHRP-like receptor rather than through GHRH receptors, establishing it as a mechanistically distinct compound ^[1].

A key aspect of ipamorelin's research profile is what it does not activate. Unlike GHRP-2 and GHRP-6, which at comparable GH-releasing concentrations also stimulate HPA-axis hormones such as ACTH and cortisol—probably through off-target engagement of CRF-pathway receptors—ipamorelin failed to raise these hormones significantly even at concentrations far exceeding the GH ED₅₀ ^[1][2]. This selectivity for GHS-R1a over other receptor types is why ipamorelin has been described as the first GHRP-receptor agonist with GH-release selectivity similar to GHRH ^[2]. Pharmacokinetic-pharmacodynamic modelling in human volunteers further showed that GH release follows saturable kinetics and returns to baseline within approximately two to three hours, consistent with a pulsatile, feedback-preserved secretory pattern rather than sustained GH elevation ^[5].

Where the evidence stands

The large majority of ipamorelin research consists of preclinical cell-culture and animal studies. These include foundational in vitro work in rat pituitary cells demonstrating potent GH release ^[1], in vivo rat and swine models confirming hormonal selectivity ^[1][2], rodent studies showing increases in bone mineral content ^[6], longitudinal bone growth in hypophysectomised animals ^[3], and attenuation of steroid-induced nitrogen wasting in rats ^[8]. Collectively, these preclinical findings established a coherent mechanistic story—selective GHS-R1a agonism leading to GH and downstream IGF-1 elevation—but they are subject to the well-known limitations of animal-to-human extrapolation, particularly for a complex neuroendocrine system.

Human data for ipamorelin are very limited. The single published pharmacokinetic/pharmacodynamic study in humans (Gobburu et al., 1999) characterised GH release kinetics in healthy volunteers and confirmed dose-proportional GH pulsatility, but it was not a therapeutic efficacy trial ^[5]. The sole published Phase 2 randomised controlled trial tested ipamorelin in postoperative ileus and failed to meet its primary endpoint, with no statistically significant difference between ipamorelin and placebo in time to tolerating a solid meal ^[10]. The FDA has explicitly concluded that it has not identified data supporting the effectiveness of ipamorelin for postoperative ileus ^[7]. Critically, no published human randomised trials exist for the body-composition, bone density, or anti-ageing research areas most commonly discussed in popular literature ^[9]. The evidence base for ipamorelin in humans therefore remains at an early, exploratory stage, and its research use is best understood as mechanistic and hypothesis-generating rather than as proof of clinical benefit.

Frequently asked questions

What is ipamorelin and what class of compound does it belong to?

Ipamorelin is a synthetic pentapeptide—a short, five-amino-acid chain—classified as a growth hormone secretagogue (GHS) and a selective agonist of the ghrelin receptor (GHS-R1a). It was originally developed by Novo Nordisk and first described scientifically in 1998. It is studied for its ability to stimulate pulsatile growth hormone release from the anterior pituitary without significantly elevating stress-related hormones such as cortisol or ACTH.

How does ipamorelin differ from other growth hormone-releasing peptides like GHRP-2 or GHRP-6?

The principal distinction identified in preclinical research is hormonal selectivity. GHRP-2 and GHRP-6 stimulate GH release but also raise ACTH and cortisol levels as off-target effects. Ipamorelin, in contrast, did not significantly elevate ACTH or cortisol even at concentrations more than 200-fold above its GH-releasing effective concentration in animal studies. This made it the first GHS described as having GH-release selectivity comparable to GHRH itself.

What does ipamorelin do to cortisol and ACTH?

In preclinical studies in swine, ipamorelin did not produce significant increases in ACTH or cortisol plasma levels, in contrast to structurally related peptides like GHRP-2 and GHRP-6. This selectivity held even at very high concentrations. It is important to note that these findings come from animal models; comprehensive human data on HPA-axis effects are lacking.

Has ipamorelin been tested in humans?

Yes, but to a limited extent. A 1999 pharmacokinetic study characterised GH release kinetics in healthy human volunteers, confirming dose-proportional, short-duration GH pulses with a plasma half-life of roughly two hours. A single Phase 2 randomised controlled trial (2014) tested ipamorelin for postoperative ileus in 117 surgical patients, but did not demonstrate a statistically significant benefit over placebo. No published human trials have evaluated ipamorelin for body composition, bone density, or other commonly discussed applications.

What happened in the only human clinical trial of ipamorelin?

The Phase 2 trial (NCT00672074), published by Beck, Sweeney, and McCarter in 2014 in the International Journal of Colorectal Disease, enrolled 117 patients undergoing bowel resection and compared ipamorelin to placebo for postoperative ileus. The key efficacy endpoint—time to tolerance of a standardised solid meal—was not significantly different between groups (25.3 hours vs. 32.6 hours, p = 0.15). Clinical development for this indication was subsequently discontinued.

What is the regulatory status of ipamorelin in the United States?

Ipamorelin has never been approved by the FDA for any therapeutic indication. In September 2023, the FDA added ipamorelin acetate to the Category 2 bulk drug substances list under Section 503B of the FD&C Act, classifying it as presenting significant safety risks and prohibiting its use in compounded medications for human administration. The FDA cited concerns about immunogenicity, impurities from unnatural amino acids, and a serious-adverse-event report from an IV gastrointestinal study.

What does the research say about ipamorelin and bone density?

Preclinical rodent studies showed that ipamorelin increased bone mineral content as measured by DXA over 12 weeks in female rats, and a separate study demonstrated longitudinal bone growth in hypophysectomised rats. The increases in cortical bone mineral content appeared to be due to greater bone dimensions rather than higher volumetric bone mineral density. These findings are animal-model data only; no published human trials have examined ipamorelin's effects on bone density.

How does ipamorelin work at the receptor level?

Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) on somatotroph cells in the anterior pituitary—the same receptor activated by the endogenous hunger hormone ghrelin. This triggers a G-protein-coupled intracellular cascade involving phospholipase C activation, IP3 generation, and a rise in intracellular calcium, which drives vesicular release of stored growth hormone as a discrete pulse. The pulsatile release pattern preserves normal hypothalamic feedback regulation of GH secretion.

Is ipamorelin the same as a GHRH analog like CJC-1295?

No. Ipamorelin is a GHRP-family peptide that activates the ghrelin receptor (GHS-R1a), while CJC-1295 is a GHRH analog that acts on the GHRH receptor (GHRHR) on pituitary somatotrophs. These are distinct receptor targets and signalling mechanisms. Ipamorelin is five amino acids long; CJC-1295 is a 30-amino-acid peptide. Both are under preclinical and early clinical research, and neither has regulatory approval for human therapeutic use.

What safety concerns have regulators identified for ipamorelin?

The FDA's Category 2 classification cited several concerns: potential immunogenicity from peptide aggregation or impurities, the presence of unnatural amino acids that complicate quality characterisation, and a published report of serious adverse events including death in an intravenous study targeting gastric motility. The agency also noted insufficient safety data for other routes of administration. These regulatory findings underscore why ipamorelin is restricted to preclinical research contexts and is not approved for human use.

Glossary

Growth hormone secretagogue (GHS)

A class of compounds that stimulate the release of growth hormone from the pituitary gland, either by acting on the ghrelin receptor (GHS-R1a) or through related pathways.

GHS-R1a (Growth Hormone Secretagogue Receptor type 1a)

A G-protein-coupled receptor expressed predominantly on pituitary somatotroph cells that is activated by both the endogenous hormone ghrelin and synthetic secretagogues such as ipamorelin to trigger GH release.

Pentapeptide

A short peptide chain composed of exactly five amino acid residues; ipamorelin's five-residue structure (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) places it in this category.

Pulsatile GH release

The natural pattern of growth hormone secretion, in which GH is released in discrete bursts rather than continuously, preserving the hypothalamic feedback mechanisms that regulate the GH axis.

ACTH (Adrenocorticotropic hormone)

A pituitary hormone that stimulates the adrenal glands to produce cortisol; off-target elevation of ACTH is a concern with some growth hormone-releasing peptides but was not observed with ipamorelin in preclinical models.

Bone mineral content (BMC)

A measure of the total amount of mineral (primarily calcium hydroxyapatite) in a given bone or body region, typically assessed by dual-energy X-ray absorptiometry (DXA).

Postoperative ileus (POI)

A temporary slowing or cessation of normal bowel motility following abdominal surgery, leading to delayed recovery of gastrointestinal function and prolonged hospitalisation.

Category 2 bulk drug substance (FDA)

A classification under the US FDA's compounding framework indicating that a substance presents significant safety risks and may not be used as an active ingredient in compounded drug preparations for human administration.

References

1. Ipamorelin, the first selective growth hormone secretagogue — European Journal of Endocrinology (PubMed)
2. Ipamorelin, the first selective growth hormone secretagogue (ResearchGate full text, Raun et al. 1998) — European Journal of Endocrinology (DOI)
3. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats — Journal of Endocrinology (PubMed)
4. Growth hormone secretagogues: history, mechanism of action, and clinical development — JCSM Rapid Communications (Wiley / DOI)
5. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers — Pharmaceutical Research (PubMed)
6. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — PMC / Translational Andrology and Urology
7. FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting: Ipamorelin-related Bulk Drug Substances — US Food and Drug Administration
8. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats — Growth Hormone & IGF Research (PubMed)
9. FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 list, ipamorelin acetate) — US Food and Drug Administration
10. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients — International Journal of Colorectal Disease (DOI)